Esragül AKINCI, İpek MUMCUOĞLU, Pınar ÖNGÜRÜ

In Vitro Activity of Tigecycline Against Acinetobacter baumannii Strains Isolated From Nosocomial Infections

Aims: Acinetobacter species usually affect hospitalized patients and are involved in many infections associated with a high mortality rate. Management of infections caused by these strains is very difficult, as the strains often display multiple drug resistance, including carbapenem resistance. Tigecycline is the most recently developed semi-synthetic broad spectrum glycylcycline antibiotic. The present study was conducted to evaluate the in vitro susceptibility of Acinetobacter baumannii strains isolated from the hospitalized patients to tigecycline. Materials and Methods: Acinetobacter isolates were collected from hospitalized patients with documented nosocomial infections between June 2005 and October 2006. Only one isolate per patient was accepted. Minimum inhibitory concentrations (MICs) were determined by E-test against tigecycline and other frequently used antibiotics. Results: Overall, 98 A. baumannii isolates were collected from the cultures of nosocomially infected patients. Tigecycline was the most active agent against A. baumannii isolates among those tested, followed by netilmicin. MIC values of tigecycline were

Anahtar Kelimeler:

Tigecycline, Acinetobacter, antibiotic, resistance

In Vitro Activity of Tigecycline Against Acinetobacter baumannii Strains Isolated From Nosocomial Infections

Keywords:

Tigecycline, Acinetobacter, antibiotic, resistance,

PDF

___

Baran G, Erbay A, Bodur H, Onguru P, Akinci E, Balaban N et al. Risk factors for nosocomial imipenem-resistant Acinetobacter baumannii infections. Int J Infect Dis 2007 May 18; [Epub ahead of print].
Hoban DJ, Bouchillon SK, Johnson BM, Johnson JL, Dowzicky MJ; Tigecycline Evaluation and Surveillance Trial (TEST Program) Group. In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004). Diagn Microbiol Infect Dis 2005; 52: 215-27.
Tognim MC, Andrade SS, Silbert S, Gales AC, Jones RN, Sader HS. Resistance trends of Acinetobacter spp. in Latin America and characterization of international dissemination of multi-drug resistant strains: five-year report of the SENTRY Antimicrobial Surveillance Program. Int J Infect Dis 2004; 8: 284-91.
Kuo LC, Teng LJ, Yu CJ, Ho SW, Hsueh PR. Dissemination of a clone of unusual phenotype of pandrug-resistant Acinetobacter baumannii at a university hospital in Taiwan. J Clin Microbiol 2004; 42: 1759-63.
Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 2005; 40: 1333-41.
Postier RG, Green SL, Klein SR, Ellis-Grosse EJ, Loh E; Tigecycline 200 Study Group. Results of a multicenter, randomized, open- label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients. Clin Ther 2004; 26: 704-14.
Oliva ME, Rekha A, Yellin A, Pasternak J, Campos M, Rose GM et al. 301 Study Group. A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections. BMC Infect Dis 2005; 5: 88.
Taccone FS, Rodriguez-Villalobos H, De Backer D, De Moor V, Deviere J, Vincent JL et al. Successful treatment of septic shock due to pan-resistant Acinetobacter baumannii using combined antimicrobial therapy including tigecycline. Eur J Clin Microbiol Infect Dis 2006; 25: 257-60.